Trial NCT04775680

View at ClinicalTrials.gov 
Org. Study IDs: ADG106-1008

Last trial update was posted on 2023-04-24

MeSH Interventions

Antibodies

MeSH Conditions

Lymphoma Lymphoma, Non-Hodgkin

Other Conditions

Non Hodgkin Lymphoma Solid Tumor

Stopping Reasons

The safety of ADG106 combined with triprilimab has been fully understood.The overall clinical benefit of enrolled subjects was limited and further development of ADG106 was reconsidered.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID